Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin

PURPOSE: Gemcitabine plus cisplatin (GemCis) is the standard first-line chemotherapy for patients with advanced biliary tract cancer (BTC). In ABC-02 study, the BTC patients received up to 6-8 cycles of 3-weekly GemCis; however, those without progression often receive more than 6-8 cycles. The clini...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Res Treat
Autors principals: Hyung, Jaewon, Kim, Bumjun, Yoo, Changhoon, Kim, Kyo-pyo, Jeong, Jae Ho, Chang, Heung-Moon, Ryoo, Baek-Yeol
Format: Artigo
Idioma:Inglês
Publicat: Korean Cancer Association 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6639240/
https://ncbi.nlm.nih.gov/pubmed/30282446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.326
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars